• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500 Edges Higher; Indivior Shares Plummet

    7/9/24 2:38:34 PM ET
    $CLNN
    $HELE
    $INDV
    $PEGY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Home Furnishings
    Consumer Discretionary
    Get the next $CLNN alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.1% on Tuesday.

    The Dow traded down 0.05% to 39,323.7 while the NASDAQ rose 0.10% to 18,422.24. The S&P 500 also rose, gaining, 0.12% to 5,579.76.

    Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday

    Leading and Lagging Sectors

    Financials shares jumped by 1.1% on Tuesday.

    In trading on Tuesday, materials shares fell by 0.6%.

    Top Headline

    Helen of Troy Limited (NASDAQ:HELE) reported soft first-quarter earnings and lowered its FY25 guidance.

    Equities Trading UP
                           

    • Soligenix, Inc. (NASDAQ:SNGX) shares shot up 379% to $9.59 after the company announced interim results for extended HyBryte treatment in early-stage CTCL patients.
    • Shares of Pineapple Energy Inc. (NASDAQ:PEGY) got a boost, surging 65% to $1.98 after the company engaged Conduit Capital to provide structural internal support, staffing, and assistance with capital-raising activities.
    • uniQure N.V. (NASDAQ:QURE) shares were also up, gaining 63% to $6.16 after the company announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington’s disease.

    Equities Trading DOWN

    • Indivior PLC (NASDAQ:INDV) shares dropped 33% to $10.28 after the company lowered its FY24 guidance.
    • Shares of Helen of Troy Limited (NASDAQ:HELE) were down 27% to $64.70 after the company reported soft first-quarter earnings and lowered its FY25 guidance.
    • Clene Inc. (NASDAQ:CLNN) was down, falling 17% to $0.2888. Clene announced a 1-for-20 reverse stock split effective July 11, 2024.

    Also Check This Out: How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings Report

    Commodities

    In commodity news, oil traded down 0.4% to $81.98 while gold traded up 0.2% at $2,368.00.

    Silver traded up 0.4% to $31.04 on Tuesday, while copper fell 0.7% to $4.5840.

    Euro zone

    European shares closed lower today. The eurozone's STOXX 600 fell 0.90%, Germany's DAX fell 1.28% and France's CAC 40 fell 1.56%. Spain's IBEX 35 Index declined 1.12%, while London's FTSE 100 fell 0.66%.

    Asia Pacific Markets

    Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.96%, Hong Kong's Hang Seng Index declining 0.01%, China's Shanghai Composite Index climbing 1.26% and India's S&P BSE Sensex gaining 0.49%.

    Japanese machine tool orders climbed by 9.7% year-over-year to JPY 133,817 million in June compared to a 4.2% rise in the prior month.

    Economics

    The NFIB Small Business Optimism Index increased to 91.5 in June from 90.5 in May, recording the strongest reading since the start of the year.

    Now Read This:

    • Qualcomm, Robinhood And 2 Other Stocks Insiders Are Selling
    Get the next $CLNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNN
    $HELE
    $INDV
    $PEGY

    CompanyDatePrice TargetRatingAnalyst
    uniQure N.V.
    $QURE
    1/28/2026$31.00Equal Weight
    Barclays
    uniQure N.V.
    $QURE
    11/4/2025Outperform → Mkt Perform
    William Blair
    uniQure N.V.
    $QURE
    8/14/2025$30.00Neutral → Outperform
    Mizuho
    Indivior Pharmaceuticals Inc.
    $INDV
    8/6/2025$27.00Buy
    H.C. Wainwright
    Indivior Pharmaceuticals Inc.
    $INDV
    7/22/2025$20.00Buy
    Jefferies
    Helen of Troy Limited
    $HELE
    7/11/2025$26.00Buy → Hold
    Canaccord Genuity
    uniQure N.V.
    $QURE
    4/1/2025$38.00Buy
    Chardan Capital Markets
    Indivior Pharmaceuticals Inc.
    $INDV
    1/28/2025$16.00Buy
    Rodman & Renshaw
    More analyst ratings

    $CLNN
    $HELE
    $INDV
    $PEGY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Soligenix Details Recent Progress and Upcoming Milestones

    PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below. Dear Friends and Shareholders, I would like to start by thanking you for your continued support, and by wishing you and your families a Happy New Year. With 2026 being an imp

    2/12/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

    ~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~ ~ Stable Lyso-Gb3 levels maintained post-dosing, regardless of enzyme replacement therapy status across all cohorts ~ ~ Six of 11 patients have discontinued enzyme replacement therapy as of data cutoff date ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 06, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase I/IIa trial of AMT-191, an investigational AAV gene

    2/6/26 7:05:00 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HELE
    $INDV
    $PEGY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on uniQure with a new price target

    Barclays initiated coverage of uniQure with a rating of Equal Weight and set a new price target of $31.00

    1/28/26 7:20:10 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure downgraded by William Blair

    William Blair downgraded uniQure from Outperform to Mkt Perform

    11/4/25 7:43:29 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    uniQure upgraded by Mizuho with a new price target

    Mizuho upgraded uniQure from Neutral to Outperform and set a new price target of $30.00

    8/14/25 8:07:02 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HELE
    $INDV
    $PEGY
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Indivior Pharmaceuticals Inc.

    SCHEDULE 13G/A - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)

    2/12/26 10:30:40 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by uniQure N.V.

    SCHEDULE 13G - uniQure N.V. (0001590560) (Subject)

    2/9/26 8:10:32 AM ET
    $QURE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Helen of Troy Limited

    SCHEDULE 13G/A - HELEN OF TROY LTD (0000916789) (Subject)

    1/30/26 2:21:36 PM ET
    $HELE
    Home Furnishings
    Consumer Discretionary

    $CLNN
    $HELE
    $INDV
    $PEGY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ryan Barbara bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 65% to 1,963 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:51:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Humphreys Keith bought $27,429 worth of Ordinary Shares (775 units at $35.39), increasing direct ownership by 15% to 5,802 units (SEC Form 4)

    4 - INDIVIOR PLC (0001625297) (Issuer)

    1/7/26 1:50:38 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HELE
    $INDV
    $PEGY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ugwumba Chidozie sold $22,792 worth of shares (5,559 units at $4.10) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/5/26 10:18:03 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $104,862 worth of shares (24,770 units at $4.23) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    2/2/26 5:10:00 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ugwumba Chidozie sold $96,045 worth of shares (19,274 units at $4.98) (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/28/26 5:01:41 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNN
    $HELE
    $INDV
    $PEGY
    Financials

    Live finance-specific insights

    View All

    Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ

    RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par

    1/28/26 7:00:00 AM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Helen of Troy Limited Reports Third Quarter Fiscal 2026 Results

    Consolidated Net Sales Decline of 3.4% GAAP Diluted Loss Per Share of $3.65 Adjusted Diluted EPS of $1.71(1) Updates Fiscal 2026 Outlook: Consolidated Net Sales of $1.758-$1.773 Billion GAAP Diluted Loss Per Share of $36.07-$35.57 Adjusted Diluted EPS of $3.25-$3.75 Helen of Troy Limited (NASDAQ:HELE), designer, developer, and worldwide marketer of branded consumer home, outdoor, beauty, and wellness products, today reported results for the three-month period ended November 30, 2025. Executive Summary - Third Quarter of Fiscal 2026 Compared to Fiscal 2025 Consolidated net sales revenue of $512.8 million compared to $530.7 million Gross profit margin of 46.9% compared to 48.

    1/8/26 6:45:00 AM ET
    $HELE
    Home Furnishings
    Consumer Discretionary

    Helen of Troy Limited Announces Earnings Release Date, Conference Call, and Webcast for Third Quarter Fiscal Year 2026 Results

    Company to Participate in the 28th Annual ICR Conference Helen of Troy Limited (NASDAQ:HELE), designer, developer, and worldwide marketer of branded consumer home, outdoor, beauty, and wellness products, today announced that the Company will release its third quarter fiscal year 2026 results before the stock market opens on Thursday, January 8, 2026. The Company will conduct a conference call to discuss its third quarter fiscal year 2026 results on the same day, Thursday, January 8, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by G. Scott Uzzell, Chief Executive Officer, and Brian Grass, Chief Financial Officer. Institutional investors and analysts interested in p

    12/22/25 4:05:00 PM ET
    $HELE
    Home Furnishings
    Consumer Discretionary

    $CLNN
    $HELE
    $INDV
    $PEGY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Indivior PLC

    SC 13G - INDIVIOR PLC (0001625297) (Subject)

    11/15/24 6:03:54 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Indivior PLC

    SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

    11/14/24 5:00:25 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Helen of Troy Limited

    SC 13G/A - HELEN OF TROY LTD (0000916789) (Subject)

    11/14/24 3:53:05 PM ET
    $HELE
    Home Furnishings
    Consumer Discretionary

    $CLNN
    $HELE
    $INDV
    $PEGY
    Leadership Updates

    Live Leadership Updates

    View All

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

    Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F

    9/23/25 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OXO Announces 2025 Chefs in Residence: Fariyal Abdullahi and Danielle Sepsy Join for a New Season Inspired by Bold Flavors and Heritage

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- OXO, an award-winning consumer brand from the Home & Outdoor business segment of Helen of Troy Limited (NASDAQ:HELE), kicks off the fifth year of its acclaimed Chefs in Residence program by welcoming two dynamic new culinary voices: Executive Chef at Hav & Mar, Fariyal Abdullahi and Founder of The Hungry Gnome, Danielle Sepsy. Now entering its fifth year, the OXO Chefs in Residence program continues to evolve with a renewed focus on emotional storytelling and globally inspired cooking. This year's theme, Cook the Mood, taps into the deep

    9/2/25 11:04:00 AM ET
    $HELE
    Home Furnishings
    Consumer Discretionary